The primary objective of this study is to determine the effect of latanoprostene bunod (LBN) ophthalmic solution 0.024% (a single dose and 7 days of once daily [QD] dosing) on 2 aspects of aqueous humor (AqH) dynamics (episcleral venous pressure [EVP] and outflow facility) in participants with ocular hypertension (OHT).

开始日期2022-05-13

申办/合作机构

Bausch & Lomb, Inc.

NCT03949244

/ Completed临床4期IIT

Effect of Nailfold Application of Latanoprostene Bunod on Nailfold Capillary Blood Flow

The purpose of this study is to look at the relationship of small blood vessels irregularities observed with an imaging system called video nailfold capillaroscopy in people with primary open-angle glaucoma. Nailfold capillaroscopy (NFC) is a video camera with a magnifying lens used for studying the movement of blood in small blood vessels. It is simple, safe and does not penetrate the skin. The skin fold that is at the tip of the finger is called the "nailfold". NFC has been used to assess blood vessel narrowing in patients with glaucoma.

开始日期2019-08-15

申办/合作机构

Icahn School of Medicine at Mount Sinai

NCT03931317

/ CompletedN/AIIT

A Randomized, Single Center, Masked, Crossover Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity in Patients With Ocular Hypertension or Primary Open Angle Glaucoma

The purpose of this research study is to compare the effect of Latanoprostene Bunod and Timolol on eye pressure and blood vessels of the back of the eye.

开始日期2018-12-03

申办/合作机构

University of California San Diego

[+1]

100 项与 Latanoprostene Bunod 相关的临床结果

登录后查看更多信息

100 项与 Latanoprostene Bunod 相关的转化医学

登录后查看更多信息

100 项与 Latanoprostene Bunod 相关的专利（医药）

登录后查看更多信息

项与 Latanoprostene Bunod 相关的文献（医药）

2025-09-01·Medical Gas Research

Corrigendum: Latanoprostene bunod: the first nitric oxide-donating antiglaucoma medication

Article

2025-06-01·Ophthalmology and Therapy

Latanoprostene Bunod 0.024% Early Experience Program (LEEP): A Canadian Initiative for Open-Angle Glaucoma and Ocular Hypertension

Article

作者: Harasymowycz, Paul ; Hutnik, Cindy M L ; Yan, David

INTRODUCTION:

Here we report the intraocular pressure (IOP) changes following treatment with latanoprostene bunod (LBN) 0.024% in patients in Canadian ophthalmology practices.

METHODS:

This real-world, open-label, 6-week, observational study collected data from 59 Canadian ophthalmologists and a total of 653 patients. Eligibility was open to all patients treated with LBN 0.024% instilled once daily for open-angle glaucoma or ocular hypertension. IOP was assessed prior to initiating LBN and after a planned 6 weeks of treatment. Patient demographics, prior treatment(s), IOP, and patient/physician satisfaction ratings were recorded. Subgroup analyses included (1) patients naïve to prior IOP-lowering medication (with or without prior selective laser trabeculoplasty [SLT]) initiating LBN; (2) patients switching from a pre-existing medication to LBN; and (3) patients adding LBN to existing medications.

RESULTS:

Of 653 patients included, 251 were naïve to previous medical antihypertensive therapy, 369 were switched to LBN from a previous medication, and 26 added LBN on top of existing medications (seven patients did not indicate status). Mean baseline IOP was 19.5 mmHg in the overall cohort and follow-up occurred over a period of 37.9 ± 7.9 days. Mean IOP was reduced by 16.3% (95% confidence interval 14.9-17.7) across all included patients. Overall IOP reduction from baseline was largest for naïve patients with no prior SLT (29.3%), with age and baseline IOP key determinants of outcomes in this group. Patient and physician satisfaction scores were high.

CONCLUSION:

This initial Canadian clinical experience of LBN in diverse patient and physician populations reflected its use in a real-world context, and demonstrated a significant IOP-lowering effect with LBN across patient groups seen in routine practice. Patient and physician satisfaction scores were high and in notable agreement.

2025-06-01·Medical Gas Research

Latanoprostene bunod: the first nitric oxide-donating antiglaucoma medication

Review

作者: Shalaby, Wesam Shamseldin ; Razeghinejad, Reza ; Soltani, Ghazaleh

Glaucoma is a chronic optic neuropathy that causes characteristic visual field defects and is considered one of the leading causes of irreversible vision loss worldwide. Lowering intraocular pressure is the only proven treatment for glaucoma. Medical therapy is usually the first-line treatment for open-angle glaucoma and ocular hypertension. Latanoprostene bunod ophthalmic drop 0.024% is a nitric oxide-donating prostaglandin F2α analog. It lowers the intraocular pressure via a dual mechanism of enhancing aqueous humor outflow through both the trabecular meshwork and uveoscleral pathways. Additionally, the nitric oxide component has shown promise in regulating ocular blood flow and promoting the survival of retinal ganglionic cells. Herein, the mechanism of action, efficacy, safety, and tolerability of the latanoprostene bunod and its effects on ocular blood flow are reviewed. Latanoprostene bunod has demonstrated strong efficacy and a favorable safety profile in both clinical trials and real-world studies. Given the promising results of latanoprostene bunod and advancements in drug delivery, topical fixed-combination and sustained-release formulations containing latanoprostene bunod and other agents targeting different intraocular pressure-lowering mechanisms may become available in the future.

112

项与 Latanoprostene Bunod 相关的新闻（医药）

2025-10-23

·GlobeNewswire-Health Care

Nicox Provides First Half 2025 Financial Results

Press Release Nicox Provides First Half 2025 Financial Results New Drug Application (NDA) submissions for NCX 470 expected in 2026 in the U.S. and ChinaCompany believes that it can finance its existing operations for at least 12 months and expects to fully repay existing financial debts in 2026 October 23, 2025 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today provided the financial results for Nicox SA (the “Company”) for the first half of 2025, as approved by the Board of Directors on October 22, 2025, and provided an update on key future milestones. “Our recent licensing payments, financing and careful cost control have positioned us with over 12 months of operational runway and the ability to repay all existing financial debts. In addition, NCX 470 marketing authorisation preparation and filing costs are taken on by our partners, who will also be responsible for the commercialisation of NCX 470 worldwide in the over $7 billion glaucoma market. This is a significant achievement for the Company, allowing us to move forward on a solid footing. Our double focus is now on both accompanying our partners in obtaining regulatory approval for NCX 470 and exploring future growth opportunities for the company.” said Gavin Spencer, Chief Executive Officer of Nicox. Key Future Milestones NCX 470 NDA submission in the United States: expected in H1 2026.NCX 470 NDA submission in China: expected shortly after submission in the U.S. NCX 470 Phase 3 clinical program in Japan: initiated in summer 2025. Managed and financed by Kowa. Subsequent eventsThe Company received license payments in August and September totalling €12.5 million relating to the signature of the NCX 470 license to Kowa and the Denali clinical trial results, in addition to €2 million related to the initiation of clinical trails on NCX 470 in Japan. Part of these payments has been used to reduce the Company’s financial debt, which amounted to €7.4 million as of 30 September 2025 and which is expected to be fully repaid in 2026.First Half 2025 Financial Results for Nicox SA Revenue for the first half of 2025 was €1.5 million (consisting principally of license payments) versus €6.1 million (including €3.1 million of net royalty payments and a license payment of €3.0 million) for the first half of 2024. The decrease mainly reflects the sale of the VYZULTA royalty stream to Soleus in the second half of 2024.Operating expenses for the first half of 2025 were €6.8 million compared to €10.1 million for the first half of 2024. The decrease primarily reflects lower payroll expenses following the cost reductions initiated in 2024, and the end of Pfizer royalty payments after the sale of the VYZULTA royalties to Soleus.Net loss for the six months ended June 30, 2025 was €8.9 million, compared to a net loss of €4.3 million for the same period in 2024. The net loss for the first half of 2025 includes a €3.0 million foreign exchange loss on US dollar-denominated receivables and cash, versus an insignificant amount in 2024.As of June 30, 2025, Nicox SA had cash and cash equivalents of €5.7 million (excluding receipt of €12.5 million of license payments and partial debt repayment after the reporting period, as set out above) as compared with €10.5 million as of December 31, 2024. Based on the expected upcoming milestones and the repayment of all existing financial debts, the Company is financed for at least 12 months. The Company remains committed to cost control and optimizing resource allocation while maintaining the capabilities required to support our strategic objectives. If any of the assumptions around estimated income or costs change, this may impact the cash runway of the Company.As of June 30, 2025, Nicox SA had financial debt of €14.8 million as compared with €15.1 million as of December 31, 2024. Only the figure related to the cash position and the debt of Nicox SA as of December 31, 2024, is audited; all other figures in this press release are non-audited. About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead late-stage development program is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa in the rest of the world. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX). For more information www.nicox.comAnalyst coverageH.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@nicox.com DisclaimerThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2024” and in section 4 of the “Rapport semestriel 2025” which are available on Nicox’s website (www.nicox.com).Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 Balance sheet(in thousands of euros)June 30, 2025December 31, 2024 ASSETS Intangible fixed assets1013Tangible fixed assets911Financial fixed assets703725 FIXED ASSETS722749 Trade receivables and related accounts1,0471,643Other receivables3,5269,349Cash assets5,70510,542Prepaid expenses1,7961,515CURRENT ASSETS12,07423,049 Unrealized foreign exchange losses and valuation differences – Assets1,50813Loan redemption premiums306610TOTAL REGULARISATION ACCOUNTS1,814623 TOTAL ASSETS14,61024,421 LIABILITIES Share Capital729692Premiums related to share capital534,264533,549Retained earnings(530,828)(508,438)Net loss for the financial year(8,948)(22,390) Total shareholders' equity(4,783)3,413 Provisions for liabilities1,50913Provisions for charges280268 Total provisions for liabilities and charges1,789281 Loans and debts from lending institutions14,81315,064Loans and other financial debts3382Accounts payable and related accounts1,4841,651Tax and social security debts414603Deferred income852735 Total current liabilities17,59618,135 Unrealized exchange gains and valuation differences - Liabilities82,592 TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY14,61024,421 Income Statement(in thousands of euros)June 30, 2025June 30, 2024 Sales of services5262Sales of finished products1,0006,067 REVENUE1,5266,069 Reversals of depreciation, amortization, provisions and transfers of expenses-449Other income144105 TOTAL OPERATING INCOME1,6706,623 Other purchases and external charges(5,795)(6,853)Taxes, duties and similar payments(44)(42)Salaries and wages(590)(1,548)Social security expenses(253)(412)Amortization(5)(9)Impairment and provisions(12)-Other expenses(124)(1,247) TOTAL OPERATING EXPENSES(6,823)(10,111) OPERATING PROFIT (LOSS)(5,153)(3,488) Other interest and similar income373398Reversal of provisions, impairment losses and transfer of expenses-13Foreign exchange gains4623 TOTAL FINANCIAL INCOME419434 Amortization, depreciation and financial provisions(2,993)(383)Interest and similar expenses(546)(817)Foreign exchange loss(676)- TOTAL FINANCIAL EXPENSES(4,215)(1,200) FINANCIAL PROFIT (LOSS)(3,796)(766) PRE-TAX LOSS(8,949)(4,254) Exceptional income from previous financial year-3EXCEPTIONAL INCOME-3 Exceptional charges from previous fiscal year-(12)EXCEPTIONAL EXPENSES-(12) EXCEPTIONAL INCOME (LOSS)-(9) Research Tax credit-- NET PROFIT & LOSS(8,949)(4,263) Attachment EN_H12025_PR_FINAL

财报引进/卖出临床3期

2025-10-14

·GlobeNewswire-Health Care

Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations

Additional pre-planned analysis of the NCX 470 Denali trial completed NCX 470 maintains robust intraocular pressure lowering at 6, 9 and 12 months Other analyses broadly in line with the trends seen for Mont Blanc Data presentations planned for upcoming ophthalmology conferences October 2, 2025 – Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that it has completed the additional pre-planned analyses of the NCX 470 Denali Phase 3 clinical trial data. These analyses confirm an efficacy profile similar to that seen in subgroup analysis of the Mont Blanc trial. In addition, reduction in intraocular pressure (IOP) was measured in the long-term safety extension period of the Denali trial from 6 months through to 12 months. NCX 470 maintained robust IOP reduction during this period with no additional safety signals seen. New Drug Applications (NDAs) for NCX 470 are in preparation for the U.S. and China. A full summary of the status of NCX 470 was given in our Press Release of September 4, 2025. The Company plans to publish further data at upcoming ophthalmology conferences. NCX 470 NDA submission in the United States: expected in H1 2026. NCX 470 NDA submission in China: expected shortly after submission in the U.S. NCX 470 Phase 3 clinical program in Japan: Program initiated in summer 2025. Managed and financed by Kowa. Similar to Mont Blanc, Denali is a randomized, multi-regional, double-masked, parallel group trial that evaluated the safety and efficacy of NCX 470 ophthalmic solution, 0.1% compared to latanoprost ophthalmic solution, 0.005% in 696 patients in 90 sites in the U.S. and China. Latanoprost is the most widely prescribed first-line therapy for open-angle glaucoma or ocular hypertension. The primary efficacy evaluation was based on reduction from baseline in mean time-matched IOP at 6 timepoints: 8 AM and 4 PM at week 2, week 6 and month 3. The Denali trial also included a long-term safety extension from 6 months through to 12 months and was jointly conducted and equally financed with our Chinese partner, Ocumension Therapeutics. Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead late-stage development program is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa in the rest of the world. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX). The content above comes from the network. if any infringement, please contact us to modify.

临床研究

2025-09-04

·GlobeNewswire-Health Care

Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed

Press Release Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed Company expects to fully repay existing financial debts in 2026NCX 470 NDA submissions in U.S. (H1 2026) and subsequently in China Milestones payable on U.S. NDA submission and on approvalGlaukos extends NCX 1728 research agreement Future strategic options under consideration including collaborations or business combinationsQ&A for shareholders available on the Nicox website: Q&A September 4, 2025 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that it expects to be able to fully repay all existing financial debts in 2026 and provided an update on its portfolio and financial situation. This follows the recent announcements of the licensing of NCX 470 to Kowa, completing our global coverage, and the positive results from our second pivotal Phase 3 clinical trial, Denali. NCX 470 has met the requirements for New Drug Applications (NDA) in the U.S. and China, with NDA submission expected in H1 2026 in the U.S., and subsequently in China. Based on these submissions, the Company expects to have recurrent revenue from 2027, in addition to milestone payments on NDA submission and approval. Costs of the NDA submissions are the responsibility of our partners.“Nicox is a revenue generating biotech with a deep and proven expertise in ophthalmology development, transactions and corporate operations. Following the recent announcement of the licensing deal for NCX 470 with Kowa, which fulfils our global licensing plans, we have also completed the second pivotal Phase 3 clinical trial, Denali, for NCX 470 in the U.S. and China. Our team will be supporting our partners, Kowa and Ocumension, in submitting the NCX 470 New Drug Applications and ensuring broad communication of the product profile and data.” said Gavin Spencer, Chief Executive Officer of Nicox. “We have demonstrated that Nicox can deliver on both the development of major clinical assets and the associated financing, whilst simultaneously implementing commercial solutions. In doing so, we have created long-term revenue streams for the Company, addressed our short-term financial needs and expect to fulfil our obligations to creditors. We believe we are now in a strong position to explore strategic options, including collaborations or business combinations.”Key Future Milestones NCX 470 New Drug Application (NDA) filing in the United States: expected in H1 2026.NCX 470 New Drug Application (NDA) filing in China: expected after submission in the U.S. Results from NCX 470 Phase 3 clinical program in Japan: Program initiated in summer 2025. Managed and financed by Kowa. Financial UpdateNCX 470 is now licensed globally, with milestone payments expected in 2026 and 2027. Royalties on net sales are expected from 2027. Based on the expected upcoming milestones and the repayment of all existing financial debts, the Company is financed into Q3 2026. The Company remains committed to cost control, optimizing resource allocation while maintaining the capabilities required to support our strategic objectives. If any of the assumptions around estimated income or costs change, this may impact the cash runway of the Company.Portfolio update NCX 470, Nicox’s lead product candidate, is licensed globally to two top-tier pharma partners, Kowa and Ocumension Therapeutics. The first two Phase 3 trials, Mont Blanc and Denali, have met the requirements for submission of NDAs in the U.S. and China. U.S. – based on Nicox’s projections, an NDA with the U.S. Food and Drug Administration (FDA) is expected to be submitted in H1 2026. Kowa is responsible for the costs of the NDA submission.China – an NDA is expected to be filed with the Chinese regulatory authorities by our partner, Ocumension, after the U.S. submission. The costs of filing the NDA are the responsibility of Ocumension.Japan – a Phase 3 confirmatory efficacy and a Phase 3 safety trial have been initiated in Japanese patients. Kowa is responsible for managing the trials, at their cost, and expect to be able to file for a marketing authorisation in Japan based on these trials.Europe – the regulatory strategy is being evaluated. NCX 1728, an NO-donating PDE-5 inhibitor, is being evaluated in a pre-clinical research program exploring indications for the treatment of glaucoma, including neuroprotection, and in the treatment of retinal diseases, under an exclusive research and option to license agreement with Glaukos. Glaukos has paid an extension fee to prolong the period of evaluation of NCX 1728 for the treatment of glaucoma. Evaluation for retinal conditions is also continuing, and is subject to different option conditions.ZERVIATE® (cetirizine ophthalmic solution), 0.24%, is currently commercialized through exclusive licensing agreements in the U.S. by Harrow, Inc. and in China by Ocumension Therapeutics for ocular itching associated with allergic conjunctivitis. VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, is exclusively licensed worldwide to Bausch + Lomb. Nicox sold the royalty revenue from VYZULTA to Soleus Capital in October 2024.NCX 4251: Changes in the U.S. dry eye market suggest that the investment in development may not be justified. NCX 4251 remains available for licensing outside the Chinese market.About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead late-stage development program is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa in the rest of the world. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX). For more information www.nicox.comAnalyst coverageH.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@nicox.com DisclaimerThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2024” which is available on Nicox’s website (www.nicox.com).Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 Attachment EN_NicoxPipelineAndStrategyUpdateSeptember2025_PR_FINAL

临床3期引进/卖出申请上市

100 项与 Latanoprostene Bunod 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10441	Latanoprostene Bunod	S01EE06	DB11660

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
青光眼	加拿大	Bausch & Lomb, Inc.	2019-05-17
开角型青光眼	美国	Bausch & Lomb, Inc.	2017-11-02
高眼压症	美国	Bausch & Lomb, Inc.	2017-11-02

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03931317 (Pubmed \| Am J Ophthalmol) 人工标引	N/A	开角型青光眼 \| 高眼压症	50	Latanoprostene Bunod	鹹廠膚範範鑰壓廠製積(醖範選蓋廠膚顧鑰糧襯) = 壓憲範觸廠淵繭遞選齋齋窪膚憲觸觸襯鬱願蓋 (顧憲選艱選製範觸鬱蓋 )	积极	2022-05-05
				Timolol	-
NCT03949244 (CTgov)	临床4期	开角型青光眼	47	Nailfold capillaroscopy+Latanoprost 0.005% (Latanoprost 0.005%)	鹽淵窪糧範鬱範膚蓋膚(範鬱鏇鏇窪願窪鬱製築) = 願膚構廠夢醖觸鹽膚願壓廠醖觸憲鹹構鹽鹽鬱 (鹽鏇艱窪淵夢廠餘衊廠, 37.76) 更多	-	2021-08-23
				Nailfold capillaroscopy+Latanoprost bunod 0.024% (Latanoprost Bunod 0.024%)	鹽淵窪糧範鬱範膚蓋膚(範鬱鏇鏇窪願窪鬱製築) = 衊鹹獵繭膚壓餘鹹顧選壓廠醖觸憲鹹構鹽鹽鬱 (鹽鏇艱窪淵夢廠餘衊廠, 78.31) 更多
ARVO Annual Meeting (ARVO2021)	N/A	青光眼	36	Latanoprostene bunod	範築鬱顧糧顧鹹觸夢鹹(獵鏇壓壓顧繭廠夢構壓) = 遞遞壓蓋範鬱鏇襯襯鏇廠願憲願鹽膚襯夢鬱積 (簾遞築願築衊醖襯觸糧 ) 更多	积极	2021-06-01
NCT00441883 (CTgov)	临床2期	开角型青光眼	176	PF-03187207 (PF-03187207 0.024% AM)	艱襯衊鹹構醖壓製廠獵(廠蓋觸窪糧餘網積鏇觸) = 窪願夢網構膚衊構廠膚憲願廠壓顧築鹽範壓鏇 (積繭範網鬱壓鹹網齋鏇, 2.772) 更多	-	2020-08-27
				PF-03187207 (PF-03187207 0.040% AM)	艱襯衊鹹構醖壓製廠獵(廠蓋觸窪糧餘網積鏇觸) = 築製醖鏇襯鑰鹽糧壓願憲願廠壓顧築鹽範壓鏇 (積繭範網鬱壓鹹網齋鏇, 2.123) 更多
NCT00595101 (CTgov)	临床2期	开角型青光眼	117	PF-0318 (PF-0318 0.006%)	糧選簾壓憲鹽衊製膚憲(襯網蓋廠積襯築鑰築壓) = 齋淵鹽鏇襯繭觸壓淵淵鏇鬱繭鬱鏇製鏇餘鑰獵 (鹹簾鑰憲蓋艱醖餘鏇衊, 2.55) 更多	-	2020-08-27
				PF-0318 (PF-0318 0.024%)	糧選簾壓憲鹽衊製膚憲(襯網蓋廠積襯築鑰築壓) = 築獵範願構艱鏇願蓋顧鏇鬱繭鬱鏇製鏇餘鑰獵 (鹹簾鑰憲蓋艱醖餘鏇衊, 3.09) 更多
ARVO2020	N/A	高眼压症 \| 青光眼	65	Latanoprostene bunod 0.024%	醖簾糧構構鏇艱醖艱鏇(遞鏇獵構獵窪鏇壓築選) = one patient reported ocular redness in one eye (0.8%) 醖獵網鬱襯獵鹽簾膚窪 (齋鬱餘糧壓鬱構範壓餘 )	-	2020-06-01
NCT01749930 (LUNAR, CTgov)	临床3期	开角型青光眼	420	BOL-303259-X (BOL-303259-X)	艱鹹繭衊選製壓窪鬱積(鏇餘簾鑰淵齋鏇窪鹹淵) = 齋鹹淵鹽膚蓋蓋構衊餘淵簾築膚簾獵廠積艱鏇 (餘鹽膚鹹網製憲範淵膚, 3.748) 更多	-	2018-11-21
				Timolol+BOL-303259-X (Timolol)	艱鹹繭衊選製壓窪鬱積(鏇餘簾鑰淵齋鏇窪鹹淵) = 顧鹽糧顧繭築顧醖積構淵簾築膚簾獵廠積艱鏇 (餘鹽膚鹹網製憲範淵膚, 3.092) 更多
NCT01749904 (APOLLO, CTgov)	临床3期	开角型青光眼	420	BOL-303259-X (BOL-303259-X)	淵顧憲願範憲衊膚糧醖(觸蓋壓壓繭廠艱範壓獵) = 蓋餘獵膚鹽鹹鹹糧廠淵構艱窪壓遞憲繭窪鑰蓋 (淵鹹蓋築範夢製夢醖淵, 3.544) 更多	-	2018-11-07
				Timolol+BOL-303259-X (Timolol)	淵顧憲願範憲衊膚糧醖(觸蓋壓壓繭廠艱範壓獵) = 積糧鹽夢壓襯遞網糧簾構艱窪壓遞憲繭窪鑰蓋 (淵鹹蓋築範夢製夢醖淵, 3.651) 更多
NCT01707381 (Constellation, CTgov)	临床2期	开角型青光眼	25	Timolol maleate (Timolol Maleate)	範壓範艱蓋膚糧淵網艱(獵簾製構構膚願糧製築) = 鹽範製艱簾衊壓廠遞構餘遞製範窪網簾鑰糧製 (範憲淵繭窪觸夢繭窪餘, 2.46) 更多	-	2018-09-04
				BOL-303259-X (BOL-303259-X)	範壓範艱蓋膚糧淵網艱(獵簾製構構膚願糧製築) = 壓膚簾觸築選範膚壓繭餘遞製範窪網簾鑰糧製 (範憲淵繭窪觸夢繭窪餘, 2.37) 更多
NCT01223378 (Voyager, CTgov)	临床2期	开角型青光眼	413	Latanoprost	選壓淵製鑰蓋範憲壓簾(製積築網襯製構窪鬱構) = 淵醖鹽廠觸齋醖鏇襯衊鏇簾鑰壓鏇壓鑰齋齋窪 (憲選積鹽繭鹹獵襯窪齋, 2.834) 更多	-	2018-07-24